NFL Biosciences SA (ALNFL.PA)
Paris · EUR · Healthcare · Biotechnology
€0.46 (-2.13%) as of
Key statistics
- Market cap
- 5.83M
- EPS (TTM)
- -0.2400
- Dividend yield
- 0.00%
- 52-week range
- 0.4225 – 1.8460
- Beta
- 1.28
- Revenue (TTM)
- 3.15k
- Profit margin
- 0.00%
- Volume
- 44.22k
About NFL Biosciences SA
NFL Biosciences SA, a biotechnology company, engages in the development of botanical drugs in France. The company's pipeline includes NFL-101, a drug candidate for smoking cessation, currently under CESTO II Phase 2 study; NFL-101, a drug candidate for smoking cessation; and NFL-301, a drug candidate for reducing alcohol consumption which is in preclinical stage. It has scientific collaboration with McLean Hospital to deepen the understanding of the mechanism of action of NFL-101, its proprietary botanical drug candidate for smoking cessation. NFL Biosciences SA was incorporated in 2006 and is headquartered in Castelnau-le-Lez, France.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Castelnau-le-Lez, France
- Employees
- 4
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.